
A Systematic Approach to the Diagnosis and Management of Abnormal Uterine Bleeding (AUB)

Nancy R. Berman MSN, ANP-BC, MSCP, FAANP
Adult Nurse Practitioner/Colposcopist
Certified Menopause Practitioner (NAMS)
The Millennium Medical Group, PC
Division of Michigan Healthcare Professionals
Farmington Hills, Michigan
Clinical Instructor
Department of Obstetrics and Gynecology
Wayne State University School of Medicine
Detroit, Michigan

1

Disclosures

Advisory Board:
Astellas
Speakers Bureau:
Astellas

2

Objectives

- Discuss the Palm-Coein classification system for abnormal uterine bleeding
 - Discuss the workup for the diagnosis of abnormal uterine bleeding
 - Discuss options for management of abnormal uterine bleeding including pharmacologic and surgical interventions
-

3

Are You Proactive in Educating Women?

What is a normal menstrual cycle and what is not?

Do you bleed for 3 to 7 days...

How do your periods effect the quality of your life?

- Life should not be hampered by menstrual cycles
- Not normal to wake up at night to change pad, not normal to have to change clothing, have special chair to sit on

Women may wrongly assume things are normal if they have heard of similar experiences from grandmothers, mothers, cousins, etc.

How do your periods effect the quality of your life: your work, sports, your sexual life, change of plans according to your period

4

Educating Women

Is your menstrual cycle normal?

When should you speak to your health care clinician?

Ask about symptoms of anemia.

Any family history of a bleeding disorder?

First years of menses often abnormal with skipped periods.

5

SO....

When addressing AUB...

6

When Furniture Gets Old... Out to the Curb!



Photo courtesy of Shutterstock.com

7

When Shoes Get Old... Out To the Trash!



Photo courtesy of Shutterstock.com

8

When Terminology Gets Old... Replace It!

- Menorrhagia
- Metromenorrhagia
- Dysfunctional Uterine Bleeding (DUB)

????????????????

9

Welcome to PALM COEIN

Systematic evaluation of AUB leading to a diagnosis and treatment plan

10

PALM COEIN




Figure 1 Basic classification system. The basic system comprises four categories that are defined by readily objective structural criteria (PALM: Polyp, Adenomyosis, Leiomyoma, and Malignancy or hyperplasia). For COEIN, the six are combined to structural events.

Marino MG, Critchley HOD, Fraser IS, Committee IPMD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. *International Journal of Gynecology & Obstetrics* 2018;145(2):392-406.

11

PALM COEIN

Most common causes of abnormal uterine bleeding:

- Uterine pathologies: STRUCTURAL
 - Polyps
 - Adenomyosis
 - Leiomyomas
 - Malignancy & hyperplasia

Marino MG, Critchley HOD, Fraser IS, Committee IPMD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. *International Journal of Gynecology & Obstetrics* 2018;145(2):392-406.

12

PALM COEIN

- Systemic conditions: NON-STRUCTURAL
 - Coagulopathies
 - Ovulatory dysfunction
 - Endometrial
 - Iatrogenic
 - Not yet classified

Heaton MW, Critchley HD, Fraser IS, Cooreman JMD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years. 2018; menopause. International Journal of Gynecology & Obstetrics. 2018;143(3):383-408.

13

A Classification System for Abnormal Uterine Bleeding

IN NONPREGNANT REPRODUCTIVE-AGED WOMEN

PALM COEIN was developed:

- To improve upon poorly defined terms and definitions
- To develop a structured approach to a frequently multifactorial clinical problem

BJOG: An International Journal of Obstetrics & Gynaecology
Volume 124, Issue 2, pages 185-189, 23 DEC 2016 DOI: 10.1111/1471-0528.14431
<http://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14431#abstract=14431>

14

A Classification System for Abnormal Uterine Bleeding

- Helps the clinician to develop a *diagnosis* for the bleeding rather than a *symptom*
- "Menorrhagia" frequently persists as an ill-defined combination of *symptom and diagnosis*
- "Heavy menstrual bleeding" or "HMB" is frequently used as a *diagnosis* rather than a *symptom*

BJOG: An International Journal of Obstetrics & Gynaecology
Volume 124, Issue 2, pages 185-189, 23 DEC 2016 DOI: 10.1111/1471-0528.14431
<http://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14431#abstract=14431>

15

FIGO System

FIGO system

- Nomenclature and definitions
- Gone are the terms 'menorrhagia', 'menometrorrhagia', and 'oligomenorrhea', and other poorly defined and inconsistently used terms.

16

FIGO System


- There are four basic criteria to define menses:
 - Frequency, duration, regularity, and volume
 - All as reported by the patient.
 - Intermenstrual bleeding is reported only when one can clearly define normal ovulatory menses.
 - Unscheduled bleeding when using hormonal medications is reported separately

17

The Menstrual Cycle

What is normal cycling?

18




19

Menses

- Proliferative phase- follicular phase, estrogen (E2) dominant
 - Endometrial growth from 0.5 to 3.5-5.0mm, relatively smooth surface
- Secretory phase- luteal phase, progesterone dominant
 - Height unchanged, becomes more glandular, sawtooth appearance
 - Menses - decreased E2 and Progesterone

Beahy and Carr 2013

20



21

Normal Cycling

- Normal interval: 21-35 days
- Only 15% of women have 28 day cycles
- Duration of flow 2-8 days, Average: 4-6
- Normal volume is 30 ml of blood

Beahy and Carr 2013

22

Endometrial Hemostasis

- Platelets involvement relatively low
- Prostaglandin E2:F2α elevated in women with heavy bleeding
 - Vasodilator and inhibits platelet aggregation
- Nitric Oxide may play a role
 - Coagulation cascade after day 1
- Possible role of enhanced fibrinolysis

Beahy and Carr 2013

23

Pictorial Bleeding Assessment Chart (PBAC)

PATIENT DIARY

PATIENT INITIALS: _____ PATIENT ID NO: _____ NEW PESSARY USED: _____
 DATE: _____ PHYSICIAN: _____ TAKING OTHER MEDICATION: _____
 OTHER: _____

DAY OF MONTH	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
1																																
2																																
3																																
4																																
5																																
6																																
7																																
8																																
9																																
10																																
11																																
12																																
13																																
14																																
15																																
16																																
17																																
18																																
19																																
20																																
21																																
22																																
23																																
24																																
25																																
26																																
27																																
28																																
29																																
30																																
31																																

Courtesy Jay Barman MD

24

Abnormal Uterine Bleeding

Definition
Causes
Diagnosis
Treatment

25

What is Abnormal Uterine Bleeding

- > 1 pad/hour for more than 1 day
 - > 7 days at a time
 - < 20 days apart
 - > 80 cc a month
 - Enough to cause anemia
 - ENOUGH TO CAUSE DISRUPTION IN LIFESTYLE
-

ACOG, Committee Opinion: April 2013 (reaffirmed 2015), number 557.

26

Prevalence

- 5% of women between 35–49
 - Up to 50% of perimenopausal women will experience AUB
 - 1.4 million women in the US annually
 - 53% of women report: periods interfere with their life
 - Compared with 23% of age-matched community controls
-

Davidson, BIR, et al. J Midwifery Womens Health, 2012.
Biller, LCO, et al. Reproductive health, 2014.

27

Diagnostic Evaluation of AUB

- The evaluation of AUB includes:
 - A thorough medical history and physical examination
 - Appropriate laboratory and imaging tests
 - Consideration of age-related factors
-

28

Diagnostic Evaluation of Abnormal Uterine Bleeding

- Medical history
- Age of menarche and menopause
 - Menstrual bleeding patterns:
 - Duration, onset and quantity
 - Severity of bleeding (clots or flooding)
 - Family or personal history of bleeding disorders
 - Pain (severity and treatment)
 - Medical conditions
-

29

Diagnostic Evaluation of Abnormal Uterine Bleeding

- Physical exam
- General physical:
 - Signs of systemic illness
 - Bruising
 - Thyromegaly
 - Hirsutism
 - Acne
 - Acanthosis nigricans (associated with insulin resistance)
 - Galactorrhea
-

30

Diagnosis

- Pelvic Examination
 - External
 - Perineal, perianal, vulvar, vaginal, urethral
 - Speculum with pap test and/or HPV test, if needed
- Bimanual exam
 - Cervical lesions
 - Uterine size and shape
 - Adnexal masses

31

Diagnostic Evaluation of Abnormal Uterine Bleeding

Laboratory tests

- Pregnancy test (blood or urine)
- Complete blood count
- Targeted screening for bleeding disorders (when indicated) *
 - Check prothrombin time (PT), partial thromboplastin time (PTT), factor VII, and Von Willebrand's factor antigen

*See Coagulopathy Slides

32

Screening for Coagulopathy

Assess for a positive screen

- Heavy menstrual bleeding since menarche
- One of the following:
 - Postpartum hemorrhage
 - Surgery-related bleeding
 - Bleeding associated with dental work

33

Screening for Coagulopathy

OR

- Two or more of the following:
 - Bruising one to two times per month
 - Epistaxis one to two times per month
 - Frequent gum bleeding
 - Family history of bleeding symptoms

34

COAGULOPATHIES

- Primary hemostasis
 - Thrombocytopenia
 - Congenital, drug induced, liver disease, lymphoma
 - Von Willebrand disease
 - 0.1-0.8% of population
- Secondary hemostasis
 - Factor VIII, XIII, fibrinogen deficiencies
 - Oral anticoagulation therapy
 - Liver disease

35

Diagnostic Evaluation of Abnormal Uterine Bleeding

- Thyroid-stimulating hormone level
- Chlamydia trachomatis

36

Diagnostic Evaluation of Abnormal Uterine Bleeding

Available Diagnostic or Imaging Tests (when indicated)

- Saline infusion sonohysterography
- Transvaginal ultrasonography
- Magnetic resonance imaging
- Hysteroscopy

37

Direct Visualization May be Necessary

- Hysteroscopy



38

Diagnostic Evaluation of Abnormal Uterine Bleeding

Available Tissue Sampling Methods (when indicated)

- Office endometrial biopsy
- Hysteroscopic directed endometrial sampling (office or operating room)

39

Screening the Endometrium

- All women older than 40 years old with a complaint of AUB
- Women with risk factors for endometrial hyperplasia (obese women, chronic anovulation, history of breast cancer)
- Women of any age with a history of unopposed estrogen exposure

Gentry-Mohr, A. and C. Karginsky (2020). "Current and future approaches to screening for endometrial cancer." *Best Pract Res Clin Obstet Gynaecol* 66: 75-87.

40

Screening the Endometrium

- Women taking an estrogen agonist/antagonist (selective estrogen receptor modulator: SERM: tamoxifen)
- Postmenopausal women who resume vaginal bleeding once menstrual cycles have ceased for 1 year

Gentry-Mohr, A. and C. Karginsky (2020). "Current and future approaches to screening for endometrial cancer." *Best Pract Res Clin Obstet Gynaecol* 66: 75-87.

41

Screening the Endometrium

- All women with abnormal endometrial cells
- Atypical glandular cells on the Pap test
 - If ≥ 35 years or at risk for endometrial neoplasia
 - Unexplained vaginal bleeding
 - Conditions suggesting chronic anovulation

Parkins RB, Guile RS, Castle PE, et al. 2018 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. *J Low Genit Tract Dis* 2020;24:102-31.

42

Using PALM COEIN

Making a diagnosis
Structural?
Non-structural?

43

AUB: PALM-COEIN

- **PALM - Structural**
 - **P** - Polyp
 - **A** - Adenomyosis
 - **L** - Leiomyoma
 - **M** - Malignancy/Hyperplasia
- **COEIN – Non-structural**
 - **C** - Coagulopathy
 - **O** - Ovulatory
 - **E** - Endometrial
 - **I** - Iatrogenic
 - **N** –Not Classified

Established by FIGO - Fédération Internationale de Gynécologie et d'Obstétrique (the International Federation of Gynecology and Obstetrics).

Meeks WG, Cushing MO, Fraser IS, Corbetta PM. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. International Journal of Gynecology & Obstetrics. 2018;143(2):393-408.

44

AUB-P

Polyps

45


AUB: P Polyps

- Endometrial proliferations
- As many as 25% may resolve spontaneously
- Mostly associated with "intermittent bleeding" as presenting sign
- Risk of malignancy – 1.7% for pre-menopause
- Risk of malignancy – 5.4% for post menopause
- Size *not* correlated with risk

Herman Y, et al. Eur J Obstet Gynecol Reprod Biol. 2013
Rai R, et al. (2002). "Endometrial polyps: diagnosis and treatment options - a review of literature." *Journal of Obstetrics and Gynaecology* 21(2): 279-287.

46

Polyps



Courtesy Barb Datto

47

PELVIC PATHOLOGY

- Polyps
 - Bleeding because of vasculature and friable
 - Bleeding is usually random
 - not necessarily related to menstruation
 - Malignancy is rare
- Inflammation
- Central blood vessel on ultrasound: must use doppler
- Not seen in fibroids

Herman Y, et al. Eur J Obstet Gynecol Reprod Biol. 2013
Rai R, et al. (2002). "Endometrial polyps: diagnosis and treatment options - a review of literature." *Journal of Obstetrics and Gynaecology* 21(2): 279-287.

48

Polyp Treatment

- Intra-Uterine polypectomy via hysteroscope
- Up to 25% regress, particularly if less than 10 mm
- Symptomatic postmenopausal polyps should be excised for histologic assessment
- Removal in infertile women improves fertility
- Surgical risks associated with hysteroscopic polypectomy are low.

AGL. 10th Issue Gynaecol 2012
Ali, N. et al (2012). "Endometrial polyps: diagnosis and treatment options - a review of literature." *Journal of Obstetrics and Gynaecology* 30(1): 279-287.

49

AUB-A

Adenomyosis

AUB: Adenomyosis

- Uterine lining grows into the adjacent muscular tissue (myometrium)
- May have no signs or symptoms – difficult to diagnose
- Excessive menstrual bleeding
- Painful menstruation and intercourse
- Uterus may be enlarged
- Hysterectomy is gold standard for diagnosis, but diagnosis may be made with:
 - High resolution ultrasound
 - Hysteroscopy

Peric H, Fraser IS. Best Pract Res Clin Obstet Gynaecol. 2006.
Roberts, L. A. (2017). "Adenomyosis and Abnormal Uterine Bleeding (AUB-A): Pathogenesis, diagnosis, and management." *Best Pract Res Clin Obstet Gynaecol* 49: 18-31.

51

Adenomyosis

- Mostly older 40's and 50's
- Pain and bleeding
- Increasingly found with infertility evaluation
- MRI and Ultrasound
- Traditional diagnosis by hysterectomy
- Attempts to treat with minimally invasive surgeries

52



53

Adenomyosis

- Treatment
 - NSAIDs
 - Hormone therapy: oral contraceptives
 - Levonorgestrel progestin containing IUDs
 - Hysterectomy
- Resolves with menopause
- Doesn't affect fertility

Peric H, Fraser IS. Best Pract Res Clin Obstet Gynaecol. 2006.
Roberts, L. A. (2017). "Adenomyosis and Abnormal Uterine Bleeding (AUB-A): Pathogenesis, diagnosis, and management." *Best Pract Res Clin Obstet Gynaecol* 49: 18-31.

54

AUB- A Pharmacologic Therapy

- NSAIDs, which are effective at reducing the amount of bleeding, discomfort and cramping
- GnRH agonist
- Combined hormonal contraceptives
- Levonorgestrel progestin containing IUDs
- Depo Medroxyprogesterone Acetate (Depo Provera)
- Prescription ant-fibrinolytic medications: Tranexamic acid (Lysteda) TID help reduce excessive blood loss

55

Tranexamic acid

- Higher plasminogen activators in the endometrium of women with AUB
- Tranexamic acid is a synthetic lysine derivative that blocks lysine binding sites on plasminogen = preventing fibrin degradation
- More effective than mefenamic acid
- Over a few cycles reduces blood loss by 60%

56

Tranexamic acid

- 1 to 1.5 g tid – qid for 3 to 4 days on day 1
- Reduce the dose in pt with renal failure
- Side effects are dose dependent
- Increased risk of DVT, contraindicated with thromboembolic disease
- Nausea, vomiting, diarrhea, and dyspepsia, as well as disturbances in color vision.

57

Levonorgestrel (LNG) IUD

- Can reduce menstrual blood loss within 5-26 days by up to 96%
- Delivers 20 mcg of levonorgestrel q 24 hrs
- There can be some variable spotting
- Approximately 20% of levonorgestrel intrauterine system users experience amenorrhea during at least 1 90-day interval by the first year after insertion

Sergison JE, Maldonado LY, Gao X, Hubacher D. Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis. Am J Obstet Gynecol. 2019 May;220(5):445-448.e6. doi: 10.1016/j.ajog.2019.05.011.

58

Oral Contraceptives

- Suppress ovarian function
- Low dosages can reduce endometrial proliferation, prostaglandin production and pain
- Consider pills containing 20 mcg or less

59

Contraceptive Ring: NuvaRing


- Non Biodegradable, flexible vaginal ring
- Delivers 15 mcg of ethinyl estradiol per day
- 120 mcg etonogestrel/day
- Works in the same way as combined oral contraceptives to reduce endometrial stimulation and proliferation

60

AUB-L

Leiomyoma (Fibroids)

61



62

AUB- L


Leiomyoma (Fibroids)

- Benign calcifications of the uterus
- In women with AUB: present in about 50%
- Estimated 50% in women > 50 years old
- Patient may present with
 - Bladder or intestinal discomfort
 - Pelvic pain or pressure
 - Heavy menstrual bleeding with clots
 - Dyspareunia
- Treatment depends on size, location & desire for fertility

ACOG Practice Bulletin No. 228: Management of Symptomatic Uterine Leiomyomas. Obstetrics & Gynecology, October 2021 • Volume 138, Issue 4 • 683
doi: 10.1097/AOG.0000000000004457

63

Leiomyoma: Fibroid



Courtesy: Bath Data

64

AUB- L Submucosal Fibroids

- AUB most likely from submucosal leiomyoma's
- Impinge on uterine cavity and endometrium
- Detected via:
 - Transvaginal Ultrasound
 - Sonohysterography – Saline infused U/S
 - Hysteroscopy
 - MRI
 - Computed tomography (CT)

65

Treatment options

- GnRH agonists: Leuprolide acetate – abruptly withdraws E₂, fibroids regress
- GnRH antagonists with add back
- Uterine Artery Embolization – interferes with blood supply leading to regression
- See & treat with Hysteroscopy used for fibroids within the endometrium
- Intrauterine morcellation
- Laparoscopic, robotic or abdominal myomectomy
- Hysterectomy-abdominal, vaginal, laparoscopic or robotic

ACOG Practice Bulletin No. 228: Management of Symptomatic Uterine Leiomyomas. Obstetrics & Gynecology, October 2021 • Volume 138, Issue 4 • 683
doi: 10.1097/AOG.0000000000004457

66

What not to do

- Blind D & C
 - No benefit
 - Will miss pathology or have incomplete removal
- Extra-uterine morcellation in the pelvic cavity via a laparoscope
 - Associated with an increased risk of seeding leiomyosarcoma into the pelvic cavity

Seidhoff, MT, Am J Obstet Gynecology, 2015

67

When is Treatment Appropriate?

- Interfering with life or lifestyle
- Pain, bleeding, pressing on other organs
- Rapid growth
- Rarely is hysterectomy necessary
- Refer to a minimally invasive Gyn specialist

68

Pharmacologic Therapy

Symptom	Direct Effect
• NSAIDS	• GnRH agonists
• Iron	• GnRh antagonists
• OC's	
• Progestin	
• Antifibrinolytic	
• LNG-IUD	

69

NSAIDS

- NSAIDS for bleeding
- Cochrane review found NSAIDS
 - More effective than placebo
 - Less effective than tranexamic acid
 - Less effective than danazol
 - Less effective than LNG-IUS
- Fewer adverse events than danazol
- No clear evidence of difference between luteal progestogen ,OCP, or antifibrinolytic
- Small number of studies, underpowered. Quality is fair.

Rodriguez M, Lethaby A, Paraghar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane database of systematic reviews (Online). 2015;9(5):CD004400.

70

Fe Therapy

- Oral most common
- IV
- Helpful for anemia associated with bleeding from fibroids

71

Tranexamic Acid

- Bleeding symptoms only
- Antifibrinolytic
- Inhibits clot dissolving enzymes in endometrium
- Potential risk for VTE
- Cyclic use for 5 days

Bryant Smith AC, Lethaby A, Paraghar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Systematic Reviews. 2018(4).

72

Tranexamic Acid

- 1300mg tid x5 days
- Superior to placebo
- Similar to cyclic progestogens
- Superior to NSAIDS
- Superior to herbal medicines(Safoof Habis and Punica granatum)
- May be less effective than LNG-IUS

Bryant-Smith AC, Lethaby A, Paraghar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. *Cochrane Database of Systematic Reviews*. 2020(6).

73

Danazol

- Oral anabolic steroid
- Hypothalamic pituitary axis, and ovaries high androgen/ low estrogen
- Masculinizing effects limits use: acne, weight gain, hot flushes, irritability, hirsutism with male pattern baldness, liver injury, breast atrophy
- Dose 50-800 mg /day
- No evidence that it affects fibroids.
- Effective in reducing bleeding, usefulness is limited by side effects.

Yu LL, Yang H, Li CH, Li L. Danazol for uterine fibroids. *Cochrane Database of Systematic Reviews*. 2009(3).
Bansalraj H, August C, Doshi A, Lethaby A. Danazol for heavy menstrual bleeding. *Cochrane Database of Systematic Reviews*. 2007(3).

74

Aromatase Inhibitors

- Letrozole and anastrozole
- Inhibits aromatization step in steroid synthesis
- Single trial
 - Adverse events: hot flushes, vaginal atrophy
 - Similar volume reduction to GnRH agonist
 - Not statistically significant
 - Poor quality study
 - Insufficient evidence to support in women with fibroids

Song H, Lu H, Neumann A, Shi G. Aromatase inhibitors for uterine fibroids. *Cochrane Database of Systematic Reviews*. 2016(6).

75

Cyclic Progestins

- Used for bleeding not volume reduction
- Low or very low quality suggests cyclic progestins are inferior to:
 - Tranexamic acid
 - Danazol
 - LNG-IUS

Bullil Rodriguez M, Lethaby A, Low C, Cameron IT. Cyclic progestogens for heavy menstrual bleeding. *Cochrane Database Syst Rev*. 2015; Aug 14(8).

76

Oral Contraceptives

- COC cyclic, extended or continuous.
- Treatment of bleeding not fibroid.
- COC effective for short term.
- No long-term studies on effectiveness with fibroids.

Wiley CE, George NA. The effectiveness of hormonal therapy in reproductive age women. *Am J Obstet Gynecol*. 2010;202(1):131-44.
ACOG Practice Bulletin No. 225: Management of Symptomatic Uterine Leiomyomas: Correction. *Obstetrics & Gynecology*. October 2021 - Volume 138 - Issue 4 - p 683 doi: 10.1097/AOG.0000000000004557

77

LNG-IUS

- Bleeding only
- Not useful for distorted or large uterine cavities

Bullil Rodriguez M, Lethaby A, Norris V. Progestogen-releasing intrauterine systems for heavy menstrual bleeding. *Cochrane Database of Systematic Reviews*. 2009(6).

78

Leuprolide Acetate

- IM injection
- Increase LH/FSH first increases estrogen, continued therapy causes drop in estrogen level
- Amenorrhea in most women
- 35-65% volume reduction within 3 months
- Add-back for fibroids only low dose replacements studied
- Progestin may decrease vasomotor symptoms and may preserve bone density but may increase fibroid volume
- Mostly studied in short term preoperative use.
- Long term use with add back

Morgan MA, Mendenhall MT, Santoro SA, et al. Add-back therapy with GnRH antagonists for uterine fibroids. *Cochrane Database of Systematic Reviews* (2018).

Levine TO, Simon N, Berman J, San-Pedro AM, Calabrese MH. A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. *Biomol Res* 2019;25(1):450-5414509.

79

GnRh Antagonists

Elagolix
Relugolix

Reduction in heavy menstrual bleeding in women with fibroids

80

Medical therapy for HMB from fibroids

- GnRH agonists and antagonists have varying limitations on duration of use
- GnRh antagonists are the newest FDA approved treatment
- The two approved medications are both limited to 24 months of use due to risk of bone loss that may not be reversible
- Should not be used in women over 35 who smoke or have uncontrolled hypertension
- Should not be used in women with a history of thromboembolic events

81

Elagolix with add-back

- Oral GnRH antagonist 300mg twice daily with estradiol 1mg and norethindrone acetate 0.5 mg add-back.
- Recently approved for use for up to 2 years.
- 791 women

Elagolix with add-back therapy for heavy menstrual bleeding in women with uterine fibroids. *New England Journal of Medicine*. 2020;382(22):228-236.

82

Elagolix

Reduction in Heavy Menstrual Bleeding in Women with Uterine Fibroids

- Primary end point (a menstrual blood loss [MBL] volume of <80 ml in the final month and a ≥50% reduction in MBL volume from baseline to the final month)
- A significantly greater percentage of women who received elagolix with add-back therapy met the criteria for the primary end point than women who received placebo.

Schaff WD et al. *N Engl J Med* 2020;382:329-340

83

Elagolix

Mean Percent Change from Baseline to 6 Months in Bone Mineral Density.

- At 6 months: Differences in the percent change in bone mineral density between women who received elagolix with add-back therapy and women who received placebo were not significant
- The differences in the percent change in bone mineral density between the elagolix-alone group and the placebo group were significant
- Except for the between-group difference at the femoral neck in Elaris UF-2.

Schaff WD et al. *N Engl J Med* 2020;382:329-340

84

Elagolix Treatment Considerations

- Exclude pregnancy OR start within 7 days from the onset of menses
- Advise women to use non-hormonal contraception during treatment and for 28 days after discontinuing Elagolix
- Assessment of BMD by DXA is recommended at baseline and periodically thereafter
- Should not be used in women over 35 who smoke, have uncontrolled hypertension or have a history of thromboembolic events
- One capsule twice a day
- Limit use to 24 months

85

Relugolix

- The trial included 768 premenopausal women with HMB associated with uterine fibroids.
- Response was defined as a volume of menstrual blood loss of less than 80 ml and a reduction of at least 50% from the baseline volume of menstrual blood loss over the last 35 days of the treatment period.
- The primary end-point analysis in each trial was the comparison of relugolix combination therapy with placebo.

Al-Hendy A et al. N Engl J Med 2021;384:630-642

86

Relugolix

Efficacy

- In the 2 trials, 72.1% and 71.2% of women responded to treatment, compared to approximately 16% with placebo
- Women achieved sustained reduction in MBL volume to 24 weeks of treatment
- At week 24, the mean reduction in MBL volume was 83.7% compared to 17.2% in the placebo group
- Change in Bone Mineral Density
 - At week 24, the mean percent change in lumbar spine BMD from baseline was -0.23% compared to +0.18% in the placebo group
 - Assessment of bone density by DXA is recommended when starting and periodically thereafter

Al-Hendy A et al. N Engl J Med 2021;384:630-642

87

Relugolix Treatment Considerations

- Exclude pregnancy and discontinue any hormonal contraceptives
- Use effective non-hormonal contraception during treatment and for 1 week after the final dose
- Should be started no later than 7 days after menses has started
- Dosing is one pill once a day
- The recommended total duration of treatment is 24 months

MyPillbox (providing information). Bridgewater, NJ: MyPillbox Sciences; 2021

88

AUB-M

- Endometrial Hyperplasia/Malignancy

89

AUB – Malignancy Endometrial Hyperplasia

- More common in younger women (< 50) with PCOS and chronic anovulation
- More common in post menopausal women with unopposed E₂ stimulation
- High index of suspicion with any bleeding
- Ultrasound to measure endometrial echo
- Family history important
- Premenopausal malignancy
 - Consider genetic testing: Lynch (hereditary non-polyposis colorectal cancer-HNPCC syndrome)

Armstrong, AJ. J Min Invas Surg. 2019.
Papadimitrakou, E. and G. Adoraki (2023). "Management of pre-, peri-, and post-menopausal abnormal uterine bleeding: When to perform endometrial sampling?" *Journal of Obstetrics and Gynaecology* 148(1): 212-269.

90

AUB- M Diagnosis

Deciphering EMB: Endometrial biopsy
Reported as:

- Benign proliferative – estrogenic
- Benign secretory – Indicates progesterone and ovulation
- Hyperplasia
- Atypical hyperplasia
- Cancer

Papantoniou, L. and G. Adewole (2022). "Management of pre-, peri-, and post-menopausal abnormal uterine bleeding: When to perform endometrial sampling?" *Endocrinology* 188(2): 212-218.

91

AUB- M Treatment

- Correct any hormonal imbalance
- Remember often seen with PCOS
- Add a progestin to her regimen if on estrogen treatment
- Progestin containing IUD
- Oral progesterone
 - Medroxyprogesterone Acetate (Provera) 10mg q hs
 - Micronized Progesterone (Prometrium) 100-200 mg q hs

Papantoniou, L. and G. Adewole (2022). "Management of pre-, peri-, and post-menopausal abnormal uterine bleeding: When to perform endometrial sampling?" *Endocrinology* 188(2): 212-218.

92

AUB- M Malignancy

- Hysterectomy with BSO, lymph node sampling
- Treatment dependent upon the level of invasion
- May need radiation and/or chemotherapy

93

AUB-C

- Coagulopathy

94

AUB – Von Willebrands

- Von Willebrands – A group of (generally) inherited disorders of coagulation related to a defect in von Willebrand factor, critical for the normal function of factor VIII
- Incidence: 13%
- History will suggest: prolonged bleeding, postpartum hemorrhage

Shankar M, BJOG, 2004

95

AUB – C Coagulopathy

- Hemophilia, thrombocytopenia – rare
- Inherited deficiencies in prothrombin, fibrinogen, factor V, factor VII, factor X, and factor XII
- Platelet function disorders: 98% of women with Bernard-Soulier syndrome or Glanzmann's thrombasthenia
- Women on anticoagulant therapies

96

Screening

- Heavy menstrual bleeding since menarche
- One of the following conditions:
 - Postpartum hemorrhage
 - Surgery-related bleeding
 - Bleeding associated with dental work
- OR
- Two or more of the following conditions:
 - Epistaxis, one to two times per month
 - Frequent gum bleeding
 - Family history of bleeding symptoms

ACOG Committee Opinion Von Willebrand Disease in Women, 2013

97

Treatment Von Willebrands

- Consultation with hematologist
- Progestin containing IUD, Implant
- Progestin Only Pill, Combined OCPs
- Tranexamic acid – antifibrinolytic
- Inhibit conversion of plasminogen to plasmin, which inhibits fibrinolysis helps to stabilize clots.
- Reduces menstrual bleeding by 30–55%

Lukes, AS, et al. Obstet Gynecol, 2010.

98

AUB-O

- Ovulatory (anovulatory)

99

AUB – O Ovulatory

- Perimenopause:
Changes in both menstrual flow and frequency are common with the following potential presentation:
- Lighter bleeding
 - Heavier bleeding
 - Duration of bleeding may change with each period
 - Cycle length often changes
 - Skipped menstrual periods

Papadimitrakou, E. and G. Adonakis (2023). "Management of pre-, peri-, and post-menopausal abnormal uterine bleeding: When to perform endometrial sampling?" [Gynecological Journal](#) 148(2): 212-218.

100

ANOVULATORY AUB

- Unpredictable in timing and volume
- Causes of anovulation
 - PCOS
 - Insulin resistance emerging role
 - Hyperprolactinemia, hypothyroidism
 - Obesity
 - Eating disorders, stress, exercise
 - Contraceptive

Papadimitrakou, E. and G. Adonakis (2023). "Management of pre-, peri-, and post-menopausal abnormal uterine bleeding: When to perform endometrial sampling?" [Gynecological Journal](#) 148(2): 212-218.

101

ANOUVULATORY AUB

- Endometrial biopsy in any chronic anovulatory AUB regardless of age.

102

Treatment

- Determination of ovulatory vs. anovulatory is critical
- Anovulatory
 - Determine etiology
 - Biopsy if > 1 year duration
 - Regardless of age

ACOG Practice Bulletin No. 136, July 2013, Reaffirmed 2018. Management of Abnormal Uterine Bleeding Associated With Ovarian Dysfunction. Obstet Gynecol. 2013 Jul;122(1):176-185. doi: 10.1097/01.AOG.0000431815.52679.50.

103

Medical Management

- Iron
 - May relieve principal symptom of fatigue 2^o to anemia
- Antifibrinolytics
 - Tranexmic acid
 - RCT 41% reduction in bleeding
 - GI side effects

ACOG Practice Bulletin No. 136, July 2013, Reaffirmed 2018. Management of Abnormal Uterine Bleeding Associated With Ovarian Dysfunction. Obstet Gynecol. 2013 Jul;122(1):176-185. doi: 10.1097/01.AOG.0000431815.52679.50.

104

Medical Management

- Cyclooxygenase Inhibitors (NSAIDS)
 - RCT show some benefit
 - Mefanemic acid
 - Naprosyn
 - Ibuprofen

ACOG Practice Bulletin No. 136, July 2013, Reaffirmed 2018. Management of Abnormal Uterine Bleeding Associated With Ovarian Dysfunction. Obstet Gynecol. 2013 Jul;122(1):176-185. doi: 10.1097/01.AOG.0000431815.52679.50.

105

Progestins

- Similar results for Levonorgestrel IUD
 - 79% reduction in bleeding
- Continuous administration
 - May work for ovulatory menorrhagia
 - Depot MPA
 - 80% amenorrhea at 1 year
 - No trials for AUB

ACOG Practice Bulletin No. 136, July 2013, Reaffirmed 2018. Management of Abnormal Uterine Bleeding Associated With Ovarian Dysfunction. Obstet Gynecol. 2013 Jul;122(1):176-185. doi: 10.1097/01.AOG.0000431815.52679.50.

106

Contraceptive Implant

- Progestin containing contraceptive implant (Nexplanon®) – Subdermal, single rod
- Progestin only – Etonorgestrel
- Highly effective contraception, 0.05% failure rate
- 3 years of benefit

ACOG Practice Bulletin No. 136, July 2013, Reaffirmed 2018. Management of Abnormal Uterine Bleeding Associated With Ovarian Dysfunction. Obstet Gynecol. 2013 Jul;122(1):176-185. doi: 10.1097/01.AOG.0000431815.52679.50.

107

Progestin Containing Implant

- Bioavailability remains constant throughout the life of the device
- There is no evidence to suggest accumulation over time
- Half-life elimination time is approximately 25 hours
- Immediate return to fertility when removed

ACOG Practice Bulletin No. 136, July 2013, Reaffirmed 2018. Management of Abnormal Uterine Bleeding Associated With Ovarian Dysfunction. Obstet Gynecol. 2013 Jul;122(1):176-185. doi: 10.1097/01.AOG.0000431815.52679.50.

108

AUB-E

- Endometrial
-

109

AUB - Endometrial

- The cause of AUB-E: Local disorders of the normal hemostatic mechanisms
 - Combination of excesses of vasodilating prostaglandins such as PG I₂ or PG E₂, or deficiencies in vasoconstricting agents such as PG F_{2α}.
 - Or Infections, such as *Chlamydia trachomatis*.
 - No commercially available tests to detect such disorders.
-

Lee, J et al. Biology of Reproduction, 2013.

110

AUB – E Endometrial

NSAID Management

- Mefenamic acid
 - 250 to 500 mg taken 2 – 4 times/day
 - Ibuprofen
 - 600 mg every 4 – 6 hours
 - All NSAIDs must be taken with food
 - Contraindicated in women with peptic ulcer
-

111

AUB-I iatrogenic

- Usually from estrogen & progestin containing contraceptives, especially progestin – only agents
 - Missed contraceptive pills
 - Certain medications that impact cytochrome p-450 pathway: anticonvulsants and some antibiotics
 - Cigarette smoking
 - Street drugs
 - Anticoagulants
-

112

Combined Contraception

- Many non-contraceptive benefits
 - Reduce endometrial height
 - Decreases bleeding, cramping, pain
 - Reduced risk of PID
 - Suppresses endometriosis
 - Reduces risk of ovarian cysts
 - Suppress the hormonal roller coaster in PCOS
-

113

AUB-N

- Not otherwise classified
-

114

AUB-N Not Otherwise Classified

- Catch-all category includes the rare and poorly defined and/or poorly examined uterine conditions such as:
 - Caesarean section scar bleeding
 - Arteriovenous malformations
 - Myometrial hypertrophy

115

Medical Management of AUB

116

Medical Options for Treating AUB

Medical options:

- Treat identified coagulation disorders
- Combined oral contraceptive – Pills, Ring, Patch
- Progesterone – Oral, IUD, IM injection
- Hormonal implant
- GnRH agonists
- GnRH antagonists
- Antifibrinolytic medications
- NSAIDs

117

Levonorgestrel Containing – Intrauterine System

- Levonorgestrel
 - Office procedure
 - 8 years
 - Provides contraception
 - May have 3-6 months of prolonged unscheduled bleeding
 - 20% of women have amenorrhea by the end of the first year
- If this is used for a Polyp or Fibroid – about 30% of women go on to other procedures

Surgent JE, Makhadmeh LY, Gao X, Huhachar D. Levonorgestrel intrauterine system associated amenorrhea: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019 May;220(5):445-448.e6. doi: 10.1016/j.ajog.2019.03.031.

118

Surgical Options for Treating AUB

119

Surgical Options for Treating AUB

- Hysteroscopic polypectomy
- Hysteroscopic myomectomy
- Abdominal myomectomy
- Endometrial ablation
- Radiofrequency ablation of fibroids
- Hysterectomy

120

Hysterectomy

- Surgical removal of the uterus
- Most definitive treatment for AUB
- Major procedure
- Abdominal, vaginal, LAVH, Robotic
- Significant risks
- Recovery period of 6 – 8 weeks
- Psychological issues

121

Alternatives to Hysterectomy

- Myomectomy
- UAE (uterine artery embolization)
- Hysteroscopic Myoma Mechanical Tissue Removal
- Polyp resection
- Endometrial Ablation
 - Traditional
 - Global

122

Myomectomy

- Preservation of fertility main advantage
- Pre-op suppression useful
- Autologous blood helpful
- Anterior incision better
- Techniques vary
- Laser, harmonic scalpel

123


Uterine Artery Embolization

124

Uterine Artery Embolization: UAE


- Option for women with AUB who are unresponsive to medical therapy and desire future fertility.^{3,18}
- Minimally invasive, catheter threaded to the specific Uterine Artery nourishing the fibroid.
- Magnetic Resonance-guided Focused Ultrasound (MRgFUS): Emerging radiologic technique : which uses MRI to identify the location of fibroids and high-intensity focused ultrasound energy to destroy leiomyomas without injury to surrounding tissues.

125



126


Angiograms



Courtesy Jay Barman MD

127

Hysteroscopic Mechanical Tissue Removal



Courtesy Jay Barman MD

128

Endometrial Ablation

Minimally invasive alternative to hysterectomy

129

Endometrial Ablation

- Appropriate for women who have finished childbearing
- Post ablation pregnancies can be very problematic, **use contraception!**
- May normalize menstruation or produce amenorrhea.⁸
- Has not been studied in postmenopausal women
- Should not be used with suspected uterine cancer or hyperplasia

Gimpelson RJ, Int J Women's Health, 2014

130

Endometrial Ablation

- Baumann (1948): 387 ablations
 - Procedure performed blindly, steelball electrode
- Goldrath (1981) ND:YAG Laser
 - Destruction performed with laser
- Rollerball
 - Electric current through the rollerball
- Trans cervical resection of the endometrium
 - Hysteroscopic loop removal of endometrium

131

Endometrial Ablation Techniques

Global Endometrial Ablation

- Hydrothermablation (HTA)
 - Hysteroscopic: free flowing hot water
- Novasure
 - Bipolar mesh
- Balloon Rx (Thermachoice)
 - 2016 Removed from market
- Minerva
 - Bipolar with plasma formation array (heat device)
- Mara
 - Controlled low pressure water vapor

132

Preparation for Endometrial Ablation

- Bipolar mesh
 - May be done at any time in the cycle
- Hydrothermablation
 - May preference thin endometrium
 - Early in cycle
 - Days to week after withdrawal bleed after 10 days of combined oral contraceptive or progestin

133

Radio Frequency Ablation of Leiomyomas

Acessa

134

MRI Subject 4




Figure 2: Baseline (pretreatment) MRI (T2) in the sagittal midline plane reveals posterior submucosal fibroid.

Figure 3: Postablation MRI (T2) in the sagittal plane reveals no fibroid.

135





Fig. 4: MRI evaluation for diagnosis of chronic abnormal uterine bleeding (AUB). No initial assessment requires the patient to have undergone 1 or a combination of endometrial, uterine volume, or abnormal frequency of bleed.

Wardlaw GJ, Harris M, Hay C, Ockler J, Michael S, Bruden J, et al. Prevalence of abnormal uterine bleeding in a general population of reproductive age. International Journal of Gynecology & Obstetrics, Volume 113, Issue 1, 2011, 2-10. doi:10.1016/j.ijgo.2010.11.011

136



Uterine evaluation: The uterine evaluation is to be guided by the history and other elements of the clinical situation such as patient age, presence of apparent chronic coagulation disorder, or the presence of other risk factors for endometrial hyperplasia.

Wardlaw GJ, Harris M, Hay C, Ockler J, Michael S, Bruden J, et al. Prevalence of abnormal uterine bleeding in a general population of reproductive age. International Journal of Gynecology & Obstetrics, Volume 113, Issue 1, 2011, 2-10. doi:10.1016/j.ijgo.2010.11.011


137

Summary

- AUB is common reason for women to seek care
- AUB requires careful history and physical assessment
- Classification of disorder helps to select appropriate Treatment
- Using PALM COEIN leads to a diagnosis that is structural or non-structural and an appropriate treatment plan!

138

Walk our patients systematically through the steps:
AUB is not a diagnosis, but a symptom that requires
a diagnosis!



139

Questions?

140

References

- AAGL. AAGL Practice Report: Practice guidelines for the diagnosis and management of endometrial polyps. *J Min Invas Gynecol*. 2012;19:3-10.
- Abbott, J. A. (2017). "Adenomyosis and Abnormal Uterine Bleeding (AUB-A): Pathogenesis, diagnosis, and management." *Best Pract Res Clin Obstet Gynaecol* 40: 68-81.
- ACOG Practice Bulletin No. 228: Management of Symptomatic Uterine Leiomyomas. *Correction, Obstetrics & Gynecology*, October 2021 - Volume 138 - Issue 4 - p 853. doi: 10.1097/AOG.0000000000004557
- ACOG Practice Bulletin No. 136, July 2013. Reaffirmed 2018. Management of Abnormal Uterine Bleeding Associated With Ovarian Dysfunction. *Obstet Gynecol*. 2013 Jul;122(1):176-185. doi: 10.1097/01.AOG.0000431815.52679.bb.
- Al-Hendy A et al. N Engl J Med 2021;384:630-642
- American College of Obstetricians and Gynecologists. *Endometrial Ablation*. Practice Bulletin. May 2007, number 81.
- American College of Obstetricians and Gynecologists. *Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women*. Committee Opinion. April 2013, (reaffirmed 2015) number 537.

141

References

- American College of Obstetricians and Gynecologists. Von Willebrand Disease in Women. Committee Opinion, December 2013, number 530.
- Beshay, VE & Carr, BR. Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle. T. Falcone and W.W. Hurd (eds.), *Clinical Reproductive Medicine and Surgery: A Practical Guide*, 31. Springer Science and Business Media New York 2013. DOI: 10.1007/978-1-4614-8837-0_2
- BJOG: An International Journal of Obstetrics & Gynaecology. Volume 124, Issue 2, pages 185-189, 23 DEC 2016 DOI: 10.1111/1471-0528.14431
- <https://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14431#abstract=14431>
- Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. *Cochrane database of systematic reviews* (Online). 2019;9(9):Cd000400
- Brito LGO, et al. Uterine leiomyoma: Understanding the impact of symptoms on women's lives. *Reprod Health*. 2014;11:10.
- Bryant-Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. *Cochrane Database of Systematic Reviews*. 2018(4).

142

References

- Gentry-Maharaj, A. and C. Kujawski (2020). "Current and future approaches to screening for endometrial cancer." *Best Pract Res Clin Obstet Gynaecol* 65: 79-97.
- Gimpelson RJ. Ten-year literature review of global endometrial ablation with the NovaSure device. *Int J Women's Health*. 2014;6:269-280.
- Goldstein, S. R. and M. A. Umsden (2017). "Abnormal uterine bleeding in perimenopause." *Glimscape* 20(5): 414-420.
- Gupta, D, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. *New Engl J Med*. 2013;368:126-137.
- Hamani Y, Eldar I, Sela HY, Voss E, Haimov-Kochman R. The clinical significance of small endometrial polyps. *Eur J Obstet Gynecol Reprod Biol*. 2013;170(2):497-500.
- Hesley GK, Gorny KR, Woodrum DA. MR-guided focused ultrasound for the treatment of uterine fibroids. *Cardiovasc Intervent Radiol*. 2013;36:5-13.
- Jabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. *Endocr Rev*. 2006;27(1):17-46.

143

References

- Jewson, M., et al. (2020). "Progesterone and abnormal uterine bleeding in menstrual disorders." *Best Pract Res Clin Obstet Gynaecol* 65: 79-97.
- Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. *Menopause*. 2011;18(4):408-411.
- Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. *Obstet Gynecol*. 2010;116:865-75.
- Marnach, M. L. and S. K. Laughlin-Tommaso (2019). "Evaluation and Management of Abnormal Uterine Bleeding." *Mayo Clin Proc* 94(2): 326-335.
- Munro MG, Critchley HOD, Fraser IS, Committee IFMD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. *International Journal of Gynecology & Obstetrics*. 2018;143(3):393-408.
- Papakostantinou, E. and G. Adonakis (2022). "Management of pre-, peri-, and post-menopausal abnormal uterine bleeding: When to perform endometrial sampling?" *Int J Gynaecol Obstet* 158(2): 252-259.
- Peric H, Fraser IS. The symptomatology of adenomyosis. *Best Pract Res Clin Obstet Gynaecol*. 2006;20(4):547-555.

144

References

- Perkins RB, Guido RS, Castle PE, et al. 2019 ASCOP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. *J Low Genit Tract Dis* 2020;24:102–31.
- Raz, N., et al. (2021). "Endometrial polyps: diagnosis and treatment options - a review of literature." *Minim Invasive Ther Allied Technol* 30(5): 278-287.
- Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. *New England Journal of Medicine*. 2020;382(4):328-340.
- Siedhoff MT, Wheeler SB, Rutstein SE, et al. Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroid tumors in premenopausal women: A decision analysis. *Am J Obstet Gynecol*. 2015;212:361.e1-68.
- Shulman LP. Chapter 2: The menstrual cycle. In: Hatcher RA, Trussell J, Nelson AL, Cates W Jr., et al. *Contraceptive Technology*, 20th ed. New York, NY: Bridging the Gap Communications, 2011:29-43.
- Song H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. *Cochrane Database of Systematic Reviews*. 2013(10).